David Braun

Dr. David Braun, a GU medical oncologist from Yale University, explores the complexities of second-line treatments for renal cell carcinoma. He delves into the different TKI options like cabozantinib and tivozanib, discussing their potency and side effects. The importance of assessing disease progression and biology is highlighted. Additionally, he reviews the risks associated with belzutifan and the management of common TKI-related adverse effects. The conversation emphasizes patient-centered care and decision-making in oncology.